CohBar (NASDAQ:CWBR – Get Rating) was downgraded by research analysts at Brookline Capital Management from a “buy” rating to a “hold” rating in a research report issued on Wednesday, PriceTargets.com reports.
CohBar Stock Down 2.3 %
NASDAQ:CWBR opened at $1.71 on Wednesday. CohBar has a twelve month low of $1.50 and a twelve month high of $15.60. The firm has a market capitalization of $4.97 million, a price-to-earnings ratio of -0.41 and a beta of 1.97. The stock’s 50 day moving average price is $2.15 and its two-hundred day moving average price is $4.79.
CohBar (NASDAQ:CWBR – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.20. As a group, analysts anticipate that CohBar will post -3.78 earnings per share for the current year.
Institutional Inflows and Outflows
CohBar, Inc, a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease.
- Get a free copy of the StockNews.com research report on CohBar (CWBR)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for CohBar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CohBar and related companies with MarketBeat.com's FREE daily email newsletter.